DDrare: Database of Drug Development for Rare Diseases

Bivv020 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
14	Chronic inflammatory demyelinating polyneuropathy	1
61	Autoimmune hemolytic anemia	1

14. Chronic inflammatory demyelinating polyneuropathy [ 145 clinical trials, 139 drugs, (DrugBank: 23 drugs), 12 drug target genes, 21 drug target pathways]

Searched query = "Chronic inflammatory demyelinating polyneuropathy", "Chronic inflammatory demyelinating poly (radiculo) neuropathy", "Multifocal motor neuropathy", "CIDP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 145 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04658472 (ClinicalTrials.gov)	December 18, 2020	1/12/2020	Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Drug: BIVV020	Sanofi	NULL	Not yet recruiting	18 Years	N/A	All	90	Phase 2	NULL

61. Autoimmune hemolytic anemia [ 90 clinical trials, 72 drugs, (DrugBank: 23 drugs), 19 drug target genes, 147 drug target pathways]

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 90 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04269551 (ClinicalTrials.gov)	June 15, 2020	29/1/2020	A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease	A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease	Autoimmune Haemolytic Anaemia	Drug: BIVV020	Sanofi	NULL	Recruiting	18 Years	N/A	All	18	Phase 1	United States;Canada;Germany;Norway;United Kingdom